What is Geneseeq?
Geneseeq Technology Inc. operates at the intersection of biotechnology and clinical diagnostics, providing advanced NGS-based solutions that facilitate personalized cancer care. The company specializes in comprehensive genomic profiling, offering actionable insights for oncologists and researchers dealing with complex solid tumors and hematologic malignancies. Through its integrated platform, Geneseeq provides central lab testing, local testing infrastructure, and bespoke research services. This multi-faceted approach enables the company to support the entire spectrum of cancer care, from initial diagnosis and prognosis to treatment selection and long-term monitoring. By collaborating with biopharma partners, Geneseeq also plays a critical role in translational research, helping to streamline drug development processes and improve patient outcomes through data-driven precision medicine.
How much funding has Geneseeq raised?
Geneseeq has raised a total of $127.9M across 3 funding rounds:
Series A
$4.8M
Series B
$9.1M
Series D
$114M
Series A (2014): $4.8M with participation from Beijing Beilu Pharmaceutical
Series B (2016): $9.1M led by Beijing D.Z Capital, Eastern Investment, and Beijing Beilu Pharmaceutical
Series D (2019): $114M supported by China Reform Holdings Corporation, Lilly Asia Ventures, and SoftBank China Venture Capital
Key Investors in Geneseeq
Lilly Asia Ventures
Lilly Asia Ventures is a premier biomedical venture capital firm with a global presence, dedicated to partnering with entrepreneurs to develop breakthrough products that improve human health.
Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co. Ltd is a major player in the pharmaceutical industry, providing significant industrial expertise and capital support to healthcare innovators.
Eastern Investment
Eastern Investment Corp is a South Korea-based investment banking firm that provides strategic financial backing to high-growth companies within the medical and technology sectors.
What's next for Geneseeq?
With the successful completion of its latest financing round, Geneseeq is strategically positioned to scale its operational capacity and enhance its technological infrastructure. The company is expected to prioritize the expansion of its proprietary genomic database, which serves as a cornerstone for its diagnostic accuracy and research efficacy. Furthermore, the influx of capital will likely support the development of new diagnostic assays and the strengthening of its biopharma partnerships, facilitating deeper integration into the drug discovery pipeline. As the precision oncology market continues to evolve, Geneseeq's focus on high-quality genomic data and clinical utility will be instrumental in maintaining its competitive advantage and driving long-term growth in the global healthcare sector.
See full Geneseeq company page
